Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> <b>Well controlled</b> = sx/SABA use ≤2 days/wk, sx ≤2 nights/mo, no interference w/ NL activity, FEV1 >80%, ≤1 exac/yr requiring PO/IV steroids (inadequate data to correlate exac freq w/ control). Most important determinant of dosing = clinician judgment of response to tx: sx, activity level, lung fxn.<br><br>
<sup>2</sup> If SABA not tolerated, ipratropium may be used as alternative.
<br><br>
<sup>3</sup> <b>Asthma biologics:</b> anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13
<br><br>
<sup>4</sup> <b>Oral steroids</b> (options listed in EPR-3 Quick Reference 2012, in alpha order): methylprednisolone, prednisolone, or prednisone: 7.5–60 mg daily (single AM dose) or every other day as needed for control. Short-course burst to gain control: 40–60 mg/day single dose (or 2 divided doses) x3–10 days.
<sup>2</sup> If SABA not tolerated, ipratropium may be used as alternative.
<br><br>
<sup>3</sup> <b>Asthma biologics:</b> anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13
<br><br>
<sup>4</sup> <b>Oral steroids</b> (options listed in EPR-3 Quick Reference 2012, in alpha order): methylprednisolone, prednisolone, or prednisone: 7.5–60 mg daily (single AM dose) or every other day as needed for control. Short-course burst to gain control: 40–60 mg/day single dose (or 2 divided doses) x3–10 days.
Detail Type
Text
Patient Type Detail Header (Long)
Maintain current tx step for well-controlled dz;<sup>1</sup> consider step down if well controlled<sup>1</sup> for ≥3 mo